Compare Nomura Holdings Inc (NMR) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nomura Holdings Inc vs Sanofi SA — how do they compare? Nomura Holdings Inc trades at $9.59 (market cap $27.55B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 3.5× Nomura Holdings Inc's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Nomura Holdings Inc for 55 Days and Sanofi SA for 94 Days on average.
| NMR | SNY | |
|---|---|---|
Market Cap | $27.55B | $95.18B |
Volume | 782,470 | 2,995,646 |
Sector | Financials | Health |
52-Week High | $10.86 | $52.34 |
52-Week Low | $6.73 | $39.51 |
Typical Hold Time | 55 Days | 94 Days |
Enterprise Value | $38.54T | $114.48B |
Dividend Yield | 3.4% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nomura Holdings (NMR) trades at $9.59, up 0.63% with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with revenue growth from $1.66T to $1.98T projected for 2026, net income margin of 20.4%, and attractive valuation ratios including P/E of 11.33. Recent news highlights technical pattern recognition and inclusion on Zacks Strong Buy lists, though cash flow trends show operational challenges.
NMR presents a mixed outlook with undervalued fundamentals against bearish technicals. Investment opportunity lies in discounted valuation and earnings momentum, but risks include negative operating cash flows, rising debt-to-asset ratios, and inconsistent earnings performance. Analyst consensus leans cautious with 67% hold ratings despite recent positive coverage.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
